Table 2.
Patient Background Characteristics
| Characteristic | All, n (%) | Recurrence Within 5 Years | Recurrence Beyond 5 Years | p Value |
|---|---|---|---|---|
| Sex | ||||
| Male/female | 313 (61.1)/199(38.9) | 104/51 | 10/7 | 0.678 |
| Age median [range] | 66 [22–86] | 66 [39–85] | 65 [38–80] | |
| Histologic type | ||||
| Adeno/nonadeno | 370 (72.0)/142 (38.0) | 98/57 | 15/2 | 0.073 |
| With/without STAS | 149 (29.0)/363 (71.0) | 64/91 | 5/12 | 0.491 |
| Pathologic stage | ||||
| IA/IB | 235 (45.9)/63 (12.3) | 24/22 | 9/1 | 0.030a |
| IIA/IIB | 25 (4.9)/82 (16.0) | 9/35 | 0/5 | |
| IIIA | 107 (20.9) | 65 | 2 | |
| Operative procedure | ||||
| Lobectomy/others | 474 (92.5)/38 (7.5) | 139/16 | 17/0 | 0.341 |
| Adjuvant chemotherapy | ||||
| UFT | 37 (7.2) | 11 | 1 | |
| Platinum doublets | 88 (17.1) | 58 | 1 | |
| Cytotoxic monotherapy | 7 (1.4) | 1 | 0 | |
| Driver mutation | ||||
| EGFR mutant | 201 (39.2) | 56 | 11 | 0.0004b |
| KRAS mutant | 42 (8.2) | 11 | 2 | |
| Other mutantsc | 21 (4.1) | 4 | 3 | |
| Wild type | 248 (48.5) | 84 | 1 | |
| Total | 512 | 155 | 17 | — |
Adeno, adenocarcinoma; STAS, spread through air spaces; UFT, an oral 5-fluorouracil derivative agent.
a
Chi-square test was performed according to stage I, II, and III between the two groups.
b
Chi-square test was performed with and without driver mutations between the two groups.
c
ALK, ROS1, and RET rearrangement.